Department of Neurology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences/Peking Union Medical College, Beijing, 100730, China.
Stanley H. Appel Department of Neurology, Nantz National Alzheimer Center, Houston Methodist Hospital, Houston, Texas 77030, United States.
Curr Alzheimer Res. 2021;18(3):265-272. doi: 10.2174/1567205018666210608120339.
Alzheimer's disease with a causative genetic mutation (AD-CGM) is an uncommon form, characterized by a heterogeneous clinical phenotype and variations in the genotype of racial groups affected.
We aimed to systemically describe the phenotype variance and mutation spectrum in the large sample size of the Peking Union Medical College Hospital (PUMCH) cohort, Beijing, China.
Next-generation sequencing (NGS) was carried out in 1108 patients diagnosed with dementia. A total of 40 Han Chinese patients with three AD gene mutations were enrolled. A systemic review of all the patients was performed, including clinical history, neurocognitive assessment, brain magnetic resonance imaging, and cerebrospinal fluid (CSF) biomarkers.
We studied the following gene mutation variants: 12 AβPP, 13 PSEN1, and 9 PSEN2, and 23 among them were novel. Most of them were early-onset, but PSEN1 mutation carriers had the youngest onset age. The commonest symptoms were similar to those of AD, including an amnestic syndrome, followed by psychiatric symptoms and movement disorder. On MRI, parietal and posterior temporal atrophy was prominent in PSEN1 and PSEN2 mutation carriers, while AβPP mutation carriers had more vascular changes. The CSF biomarkers profile was indistinguishable from sporadic AD.
We identified a small group of AD-CGM subjects representing 3.6% among more than 1000 demented patients in the PUMCH cohort. These subjects usually presented with early-onset dementia and exhibited significant clinical and genetic heterogeneity. Identification required complete screening of genetic mutations using NGS. Although family history was usually present, we found non-familial cases of all three genetic mutations.
伴有致病基因突变的阿尔茨海默病(AD-CGM)是一种罕见的形式,其临床表型呈异质性,受影响的种族群体的基因型存在差异。
我们旨在系统描述中国北京协和医院(PUMCH)队列的大样本量中 AD-CGM 患者的表型变异和突变谱。
对 1108 例诊断为痴呆的患者进行下一代测序(NGS)。共纳入 40 名携带 3 种 AD 基因突变的汉族患者。对所有患者进行系统回顾,包括临床病史、神经认知评估、脑磁共振成像和脑脊液(CSF)生物标志物。
我们研究了以下基因突变变体:12 个 AβPP、13 个 PSEN1 和 9 个 PSEN2,其中 23 个是新的。它们大多数为早发性,但 PSEN1 突变携带者的发病年龄最小。最常见的症状与 AD 相似,包括遗忘综合征,其次是精神症状和运动障碍。在 MRI 上,PSEN1 和 PSEN2 突变携带者的顶叶和颞叶后部萎缩明显,而 AβPP 突变携带者的血管变化更多。CSF 生物标志物谱与散发性 AD 无法区分。
我们在 PUMCH 队列的 1000 多名痴呆患者中发现了一小群 AD-CGM 患者,占比为 3.6%。这些患者通常表现为早发性痴呆,表现出显著的临床和遗传异质性。需要使用 NGS 对基因突变进行全面筛查才能确定。尽管通常存在家族史,但我们发现了三种基因突变的非家族性病例。